SG Americas Securities’s Aimmune Therapeutics AIMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-122,812
| Closed | -$4.23M | – | 3560 |
|
|
2020
Q3 | $4.23M | Sell |
122,812
-25,301
| -17% | -$539K | 0.03% | 404 |
|
|
2020
Q2 | $2.48M | Buy |
148,113
+140,040
| +1,735% | +$2.38M | 0.02% | 693 |
|
|
2020
Q1 | $116K | Buy |
8,073
+2,001
| +33% | +$51.1K | ﹤0.01% | 2893 |
|
|
2019
Q4 | $203K | Sell |
6,072
-5,555
| -48% | -$155K | ﹤0.01% | 2462 |
|
|
2019
Q3 | $243K | Buy |
+11,627
| New | +$237K | ﹤0.01% | 2261 |
|
|
2019
Q2 | – | Sell |
-26,071
| Closed | -$583K | – | 3592 |
|
|
2019
Q1 | $583K | Sell |
26,071
-72,067
| -73% | -$1.7M | 0.01% | 1713 |
|
|
2018
Q4 | $2.35M | Buy |
+98,138
| New | +$2.54M | 0.02% | 777 |
|
|
2017
Q4 | – | Sell |
-8,430
| Closed | -$209K | – | 3819 |
|
|
2017
Q3 | $209K | Buy |
8,430
+2,979
| +55% | +$64.2K | ﹤0.01% | 2550 |
|
|
2017
Q2 | $112K | Buy |
5,451
+499
| +10% | +$9.52K | ﹤0.01% | 2839 |
|
|
2017
Q1 | $108K | Sell |
4,952
-11,684
| -70% | -$240K | ﹤0.01% | 2946 |
|
|
2016
Q4 | $340K | Buy |
16,636
+7,761
| +87% | +$159K | ﹤0.01% | 1961 |
|
|
2016
Q3 | $133K | Buy |
+8,875
| New | +$120K | ﹤0.01% | 2834 |
|
SG Americas Securities's AIMT Position: Q4 2020 in Review
SG Americas Securities sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 122,812 shares — an estimated $4.23M sold.
SG Americas Securities first reported a position in AIMT in Q3 2016 and held it in 12 quarters. The position peaked at $4.23M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.
- SG Americas Securities reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
- SG Americas Securities sold 122,812 Aimmune Therapeutics shares in Q4 2020, an estimated $4.23M.
- SG Americas Securities first reported a position in Aimmune Therapeutics in Q3 2016 and held it in 12 quarters.
- SG Americas Securities's Aimmune Therapeutics position peaked at $4.23M in Q3 2020.
- 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.
Based on SG Americas Securities's 13F filing for Q4 2020, filed 4 Feb 2021.